Panel Discussion | How important are TAVR Hemodynamics and What to do About It?

Saturday, March 8, 2025

9:04 AM - 9:20 AM ET

Moderator(s)

Ankur Kalra, MD

Interventional Cardiologist
Franciscan Health, United States

No relationships to disclose
Kimberly A. Skelding, MD, FACC FAHA FSCAI

Division Chief of Cardiovascular Services
RWJ Barnabas Health Jersey City
ridgewood, New Jersey, United States

No relationships to disclose
Thomas Waggoner, DO, FACC, FSCAI, FSVM, RPVI

Director Structural Heart, Director Cardiovascular Research, Direct Advanced Cardiac Fellowships.
US Heart & Vascular, Tucson Medical Center

No relationships to disclose

Panel Discussant(s)

Hemal Gada, MD

Structural Interventional Cardiologist
UPMC Central PA

Disclosure(s): Abbott Vascular Devices: Consultant (Ongoing); Boston Scientific Corporation: Consulting Fees (e.g., advisory boards) (Ongoing); Edward Lifesciences: Consultant (Ongoing); innovative cardiovascular solutions: Consultant (Ongoing); Medtronic, Inc: Consulting Fees (e.g., advisory boards) (Ongoing); Pi-Cardia: Consultant (Ongoing)
Howard C. Herrmann, MD, FACC, MSCAI

John Bryfogle Professor of Cardiovascular Medicine, Emeritus
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania, United States

Disclosure information not submitted.
Michael H. Joner, MD

Associate Professor Interventional Cardiology
Deutsches Herzzentrum Muenchen
Munich, Bayern, Germany

No relationships to disclose
Arnav Kumar, MD, MSCR

Interventional Cardiologist Structural Heart Valve Specialist Assistant Professor of Medicine
University of Houston, HCA Medical Center
Houston, Texas, United States

No relationships to disclose
Grant W. Reed, MD, MSc

Program Director, Interventional Cardiology Fellowship
Cleveland Clinic
Cleveland, Ohio, United States

No relationships to disclose

Disclosure(s):

Ankur Kalra, MD: No financial relationships to disclose

Kimberly A. Skelding, MD, FACC FAHA FSCAI: No financial relationships to disclose

Thomas Waggoner, DO, FACC, FSCAI, FSVM, RPVI: No financial relationships to disclose

Hemal Gada, MD: Abbott Vascular Devices: Consultant (Ongoing); Boston Scientific Corporation: Consulting Fees (e.g., advisory boards) (Ongoing); Edward Lifesciences: Consultant (Ongoing); innovative cardiovascular solutions: Consultant (Ongoing); Medtronic, Inc: Consulting Fees (e.g., advisory boards) (Ongoing); Pi-Cardia: Consultant (Ongoing)

Howard C. Herrmann, MD, FACC, MSCAI: Abbott: Grant/Research Support (Ongoing); Affluent Medical: Consultant (Ongoing); Caranx: Consultant (Ongoing); Edwards Lifesciences: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Massachusetts Medical Society: Editorial consultant (Ongoing); Medtronic: Consultant (Ongoing), Grant/Research Support (Ongoing); Microinterventional Devices: Consultant (Ongoing); Shockwave: Grant/Research Support (Ongoing); Wells Fargo: Consultant (Ongoing)

Michael H. Joner, MD: No financial relationships to disclose

Arnav Kumar, MD, MSCR: No financial relationships to disclose

Grant W. Reed, MD, MSc: Abbott Laboratories: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Boston Scientific Corporation: Consulting Fees (e.g., advisory boards) (Ongoing); Edwards Lifesciences: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)